Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles M Perou

Showing results (331-340 of 447) with videos related to

Pageof 45
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Supervised risk predictor of breast cancer based on intrinsic subtypesJoel S Parker, Michael Mullins, Maggie C U Cheang, et al.
Cancer Research|March 26, 2026
Integrated Multi-omic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast CancerAng Gao, Parth H Khatri, Gui Ma, et al.
Biorxiv : the Preprint Server for Biology|June 26, 2025
Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast CancersDiego A Pedroza, Xueying Yuan, Fengshuo Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2021
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based TherapyTomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, et al.
Scientific Reports|July 11, 2024
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancerNatàlia Lorman-Carbó, Olga Martínez-Sáez, Aranzazu Fernandez-Martinez, et al.
Science Advances|April 26, 2017
A murine preclinical syngeneic transplantation model for breast cancer precision medicineLorenzo Federico, Zechen Chong, Dong Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2023
Supervised Risk Predictor of Breast Cancer Based on Intrinsic SubtypesJoel S Parker, Michael Mullins, Maggie C U Cheang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2010
Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell typesMatthew D Wilkerson, Xiaoying Yin, Katherine A Hoadley, et al.
Ebiomedicine|June 23, 2021
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapyNuria Chic, Francesco Schettini, Fara Brasó-Maristany, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2012
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trialMaggie C U Cheang, K David Voduc, Dongsheng Tu, et al.
Pageof 45

Showing results (331-340 of 447) with videos related to

Sort By:
Pageof 45
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Supervised risk predictor of breast cancer based on intrinsic subtypesJoel S Parker, Michael Mullins, Maggie C U Cheang, et al.
Cancer Research|March 26, 2026
Integrated Multi-omic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast CancerAng Gao, Parth H Khatri, Gui Ma, et al.
Biorxiv : the Preprint Server for Biology|June 26, 2025
Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast CancersDiego A Pedroza, Xueying Yuan, Fengshuo Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2021
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based TherapyTomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, et al.
Scientific Reports|July 11, 2024
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancerNatàlia Lorman-Carbó, Olga Martínez-Sáez, Aranzazu Fernandez-Martinez, et al.
Science Advances|April 26, 2017
A murine preclinical syngeneic transplantation model for breast cancer precision medicineLorenzo Federico, Zechen Chong, Dong Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2023
Supervised Risk Predictor of Breast Cancer Based on Intrinsic SubtypesJoel S Parker, Michael Mullins, Maggie C U Cheang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2010
Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell typesMatthew D Wilkerson, Xiaoying Yin, Katherine A Hoadley, et al.
Ebiomedicine|June 23, 2021
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapyNuria Chic, Francesco Schettini, Fara Brasó-Maristany, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2012
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trialMaggie C U Cheang, K David Voduc, Dongsheng Tu, et al.
Pageof 45